Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01309854 · ClinicalTrials.gov registry record · Phase 1
Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01309854 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 15 participants.
The verdict
NCT01309854, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the drug interaction between fostamatinib and pioglitazone by comparing the safety, tolerability and plasma concentration of pioglitazone when administered alone and with fostamatinib in healthy subjects.
Interventions
- DRUG pioglitazone
- DRUG fostamatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01309854
The ClinicalTrials.gov registry entry for NCT01309854 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pioglitazone is the first listed.
NCT01309854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01309854 about?
NCT01309854 is a clinical study titled "Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects". The purpose of this study is to investigate the drug interaction between fostamatinib and pioglitazone by comparing the safety, tolerability and plasma concentration of pioglitazone when administered alone and with fostamatinib in healthy subjects.
What is the current status of trial NCT01309854?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2011-03. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01309854?
The interventions under investigation include: pioglitazone (DRUG), fostamatinib (DRUG).
Who is sponsoring clinical trial NCT01309854?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.